## Computational Modeling of Protein-Ligand Interactions



Hao FAN
https://web.bii.a-star.edu.sg/~fanh https://www.a-star.edu.sg/bii/research/bsmd/sldd

## Mechanism - Engineering - Discovery - Safety



Structure \& Function Mechanism

Enzyme Engineering


## Structure \& Function Mechanism




## Ligand Discovery

(GIS, NCCS, NUS, BII)


Chemical Safety

(IMCB, BII, NUS, DSO)


## Publications and Inventions

## Structure \& Function Mechanism

(Krishna, Shreyas, Ravi)

1) Hepatic mitochondrial NAD+ transporter SLC25A47 activates AMPKa mediating lipid metabolism and tumorigenesis. Hepatology. 2023
2) The stability of R -spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of $\alpha \mathrm{C}-\beta 4$ loop. Science Advances. 2021
3) Molecular basis for lipid recognition by the prostaglandin D2 receptor CRTH2. PNAS. 2021
4) Structure of human steroid $5 \alpha$-reductase 2 with the anti-androgen drug finasteride. Nature Communications. 2020
5) Structure of formylpeptide receptor 2-Gi complex reveals insights into ligand recognition and signaling. Nature Communications. 2020

## > Enzyme Engineering (Yossa, Shreyas, Ravi)

1) Lim et al. Structure-guided engineering of prenyltransferase NphB for high-yield and regioselective cannabinoid production. ACS Catalysis. 2022
2) $\mathrm{https}: / /$ chemrxiv.org/engage/chemrxiv/article-details/63ec488ffffb 27 a 31 fccf 1 e 4
3) Patent No. 10202260537Q. Title: "A computational-experimental workflow to increase enzyme evolution speed".

## > Ligand Discovery (Chaitanya, Weina, Lina)

1) Inventory disclosure SHIP Ref No TEC-20-85. Title: "The discovery of a BRAF-specific allosteric inhibitor, T009 for treating cancers that have developed resistance to RAF inhibitors".
2) Low et al. Molecular docking-aided identification of small molecule inhibitors targeting $\beta$-catenin-TCF4 interaction. iScience. 2021
3) Patent No. PCT/SG2020/050512. Title: "Heterocyclic Compounds as Modulators of Beta-Catenin/Tcf4 Interaction".
4) Patent No. SP106288SG. Title: "Galectin-based peptide cocktail therapy for hypertension and heart failure".
5) In-Silico Identified New Natural Sortase A Inhibitors Disrupt S. aureus Biofilm Formation. Int. J. Mol. Sci. 2020

## > Chemical Safety

## (Ravi, Wan, Chaitanya, Julian)

1) Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A. Drug Metab Dispos. 2022
2) Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5. Mol Pharmacol. 2021
3) Structure-based virtual screening of CYP1A1 inhibitors: towards rapid tier-one assessment of potential developmental toxicants. Arch. Toxicol. 2021
4) Mechanism-based Inactivation of Cytochrome P450 3A4 by Benzbromarone. Mol Pharmacol. 2021
5) Virtual screening of potentially endocrine-disrupting chemicals against nuclear receptors and its application to identify PPARg-bound fatty acids. Arch. Toxicol. 2020

## Acknowledgement

My group
R.N.V. Krishna Deepak

Ravi Kumar Verma
Shreyas Supekar
Yossa Dwi Hartono
Chaitanya Kumar Jaladanki
Weina Du
Lina Zhao
Achal Ajeet Rayakar
Wan Wei
Julian Behn

## Collaborator

Cheng Zhang (Pittsburg)
Ligong Chen (Tsinghua)
Jiancheng Hu (NCCS)
Wen Shan Yew (NUS)
Sebastian Maurer-Stroh
Yee Hwee Lim (ISCE2)
Ee Lui Ang (SIFBI)
Ramanuj DasGupta (GIS)
Justin Jang Hann Chu (NUS)
Tuck Wah Soong (NUS)
Hwee Kuan Lee
Li Cheng
Lit-Hsin Loo
Hai Wei Song (IMCB)
Eric Chun Yong Chan (NUS)
Siew Bee Ng
Yoganathan Kanagasundaram

## Funding

Bioinformatics Institute
A*STAR
IAF-PP
SIBER, GAP
NMRC OF-IRG
MTC IRG
SG UNITED
a Singapore Together initiative
${ }^{\square}$ DSO

